# Sandra M. Swain

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/sandra-m-swain/

## Facts

| Field | Value |
| --- | --- |
| Citations | 52,981 |
| Field | Breast Cancer Treatment Studies |
| h-index | 87 |
| i10-index | 268 |
| Last Known Institution | Georgetown University |
| OpenAlex ID | https://openalex.org/A5067203408 |
| ORCID iD | https://orcid.org/0000-0002-1320-3830 |
| Works | 556 |

## Researcher papers

- [Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer](https://scholariq.org/papers/trastuzumab-plus-adjuvant-chemotherapy-for-operable-her2-positive-breast-cancer/)
- [Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis](https://scholariq.org/papers/pathological-complete-response-and-long-term-clinical-benefit-in-breast-cancer/)
- [3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)](https://scholariq.org/papers/3rd-eso-esmo-international-consensus-guidelines-for-advanced-breast-cancer-abc-3/)
- [Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials](https://scholariq.org/papers/long-term-outcomes-for-neoadjuvant-versus-adjuvant-chemotherapy-in-early-breast/)
- [Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study](https://scholariq.org/papers/pertuzumab-trastuzumab-and-docetaxel-for-her2-positive-metastatic-breast-cancer/)
- [Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up](https://scholariq.org/papers/early-breast-cancer-esmo-clinical-practice-guideline-for-diagnosis-treatment-and/)
- [International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment](https://scholariq.org/papers/international-expert-panel-on-inflammatory-breast-cancer-consensus-statement-for/)
- [Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials](https://scholariq.org/papers/increasing-the-dose-intensity-of-chemotherapy-by-more-frequent-administration-or/)
- [6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)](https://scholariq.org/papers/6th-and-7th-international-consensus-guidelines-for-the-management-of-advanced/)

## Researcher topics

- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Estrogen and related hormone effects](https://scholariq.org/topics/estrogen-and-related-hormone-effects/)

## Researcher university

- [Georgetown University](https://scholariq.org/institutions/georgetown-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.